Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.7% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares fell 3.7% during mid-day trading on Monday . The stock traded as low as $11.70 and last traded at $11.94. 788,735 shares changed hands during trading, a decline of 50% from the average session volume of 1,588,775 shares. The stock had previously closed at $12.39.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Monday. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Trading Down 3.7 %

The company’s fifty day moving average is $29.36 and its two-hundred day moving average is $25.32. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market cap of $21.51 million, a price-to-earnings ratio of 0.00 and a beta of 2.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($23.00) earnings per share for the quarter, topping the consensus estimate of ($203.00) by $180.00. The company had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth approximately $40,000. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth approximately $72,000. Finally, Geode Capital Management LLC lifted its position in shares of Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after buying an additional 1,855,907 shares in the last quarter. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.